We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Collection Tubes Compared for Glucose Values

By LabMedica International staff writers
Posted on 04 Apr 2013
Blood glucose concentrations in samples collected with barrier serum tubes and plasma tubes with anticoagulants have been compared. More...


Blood specimens for plasma glucose analysis have been collected in tubes which contain sodium fluoride (NaF), to prevent coagulation and glycolysis, and an inhibitor potassium oxalate (KOx) and compared with samples collected in barrier serum tubes.

Scientists at the University of Ottawa (ON, Canada) collected serum and plasma samples were under field conditions from a single draw of 3,692 individuals. Collection was performed using a 4.0 mL plasma NaF/KOx tube and a 7.5 mL serum separator tubes (SST) tube; both are from the BD Vacutainer range (Becton–Dickinson; Franklin Lakes, NJ, USA).

Plasma and serum specimens were analyzed on a Vitros 5.1 FS analyzer (Ortho-Clinical Diagnostics Inc. Raritan, NJ, USA) using the VITROS GLUSlide method, which has a multilayered, analytical element coated on a polyester support. Paired specimens from both SST and NaF/KOx draws from each respondent were analyzed using the same lot of reagent, eliminating any lot-to-lot variability in the results.

A total of 495 paired samples were used in the final comparison. There was a high rate of 86.2% hemolysis in the NaF/KOx tubes, while hemolysis was infrequently observed with only 2% the SST tubes. Comparing only blood draws where no hemolysis was observed in both tubes showed no effect of tube type on serum/plasma glucose concentrations. This was also observed when data was restricted to cases when only SST samples were not hemolyzed. The mean glucose concentrations measured in plasma was 4.85 ± 1.25 mmol/L and in serum was 4.84 ± 1.24 mmol/L, which was not significantly different.

The authors concluded that both collection tubes can be used under survey collection and processing conditions to measure glucose with this assay system with no difference in reported results. The elimination of NaF/KOx tubes would provide process and operational advantages and a significant cost saving measure for national population-based surveys. The study was published in the March 2013 issue of the journal Clinical Biochemistry.

Related Links:
University of Ottawa
Becton–Dickinson
Ortho-Clinical Diagnostics Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.